Viridian Therapeutics (NASDAQ:VRDN) reported quarterly losses of $(0.90) per share which beat the analyst consensus estimate of $(1.05) by 14.29 percent. This is a 3.45 percent decrease over losses of $(0.87) per share from the same period last year. The company reported quarterly sales of $141.000 thousand which beat the analyst consensus estimate of $27.500 thousand by 412.73 percent. This is a 95.83 percent increase over sales of $72.000 thousand the same period last year.